Investigation of β-catenin and E-cadherin expression in dukes B2 stage colorectal cancer with tissue microarray method. Is it a marker of metastatic potential in rectal cancer?

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 429-437

  Tóth, László ^a   András, Csilla ^a   Molnár, Csaba ^a   Tanyi, Miklós ^a   Csiki, Zoltán ^b   Molnár, Péter ^a   Szántó, János ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

catenin and E cadherin; Colorectal cancer; Metastasis; TMA

Indexed keywords

BETA CATENIN; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PROTEIN EXPRESSION; RECTUM CANCER; RISK ASSESSMENT; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; CELL MEMBRANE; CELL NUCLEUS; COLON; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECTUM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863448322     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9463-y     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Graziano F, Cascinu S (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes B colorectal cancer patients: how much evidence is enough? Ann Oncol 14:1026-1038
3. Iqbal S, Stoehlmacher J, Lenz HJ (2004) Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest 22:762-773
4. Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354
5. Tsanou E, Peschos D, Batistatou A et al (2008) The E-cadherin adhaesion molecule and colorectal cancer. A global literature approach. Anticancer Res 28:3815-3826
6. Kikuchi A (2000) Regulation of β-catenin signalling in the Wnt pathway. Biochem Bioph Res Co 268:243-248
7. Lugli A, Zlobec I, Minoo P et al (2007) Prognotic significance of the wnt signalling patway molecules APC, β-catenin and Ecadherin in colorectal cancer - a tissue microarray based analysis. Histopathology 50:453-464
8. Tetsu O, McCormick F (1999) β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426
9. Ikeda S, Kishida S, Yamamoto H et al (1998) Axin, a negative regulator of the Wnt signalling pathway, forms a complex with GSK-3 beta and β-catenin and promotes GSK3 beta dependent phosphorylation of β-catenin. EMBO J 17:1371-1384
10. Chen S, Liu J, Li G et al (2008) Altered distribution of β-catenin and prognostic roles in colorectal carcinogenesis. Scand J Gastroenterol 43:456-464
11. Han SA, Chun H, Park CM et al (2006) Prognostic significance of β-catenin in colorectal cancer with liver metastasis. Clin Oncol 18:761-767
12. Horst D, Reu S, Kriegl L et al (2009) The intratumoral distribution of nuclear β-catenin is a prognostic marker in colon cancer. Cancer 115:2063-2070
13. Battifora H (1986) The multitumor (sausage) tissue block: Novel method for immunhistochemical antibody testing. Lab Invest 55:244-248
14. Fernebro E, Dictor M, Bendhal P et al (2002) Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126:702-705
15. Markowitz SD, Bertagnolli MM (2009) Molecular basis of colorectal cancer. N Engl J Med 361:2449-60
16. Buhmeida A, Elzagheid A, Algars A et al (2008) Expression of the cell-cell adhaesion molecule β-catenin in colorectal carcinomas and their metastasis. APMIS 116:1-9
17. Hugh TJ, Dillon SA, Taylor BA et al (1999) Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 80:1046-1051
18. Pancione M, Forte N, Sabatino L et al (2009) Reduced β-catenin and peroxisome proliferator-activated receptor gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor associated macrophages, cyclooxigenase 2 and patient outcome. Hum Pathol 40:714-725
19. Wong SCC, Lo ESF, Chan AKC et al (2003) Nuclear β-catenin as a potential prognostic and diagnostic marker in patients with colorectal cancer from Hong Kong. J Clin Pathol Mol Pathol 56:347-352
20. Wong SCC, Lo ESF, Chan AKC et al (2004) Prognostic and diagnostic significance of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 10:1401-1408
21. Tatsuguchi A, Kishida T, Fujimori S et al (2006) Differential expression of cyclo-oxigenase-2 and nuclear β-catenin in colorectal cancer tissue. Aliment Pharm Therap 24:153-159
22. Horst D, Kriegl L, Engel J et al (2009) CD133 and nuclear β-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45:2034-2040
23. Nosho K, Yamamoto H, Takahashi T et al (2007) Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 28:1364-1370
24. Resnick MB, Routhier J, Konkin T et al (2004) Epidermal growth factor receptor, c-met, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 10:3069-3075
25. Hoos A, Nissan A, Stojadinovic A et al (2002) Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 8:3841-3849
26. Kallioniemi OP, Wagner U, Kononen J et al (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10:657-662
27. Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847
28. Egervari K, Szollosi Z, Nemes Z (2007) Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 203:169-177
29. Sapino A, Marchio C, Senetta R et al (2006) Routine assesment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 449:288-96
30. Fernebro E, Bendhal P, Dictor M et al (2004) Immunohistochemical patterns in rectal cancer: applications of tissue microarray with prognostic correlations. Int J Cancer 111:921-928
31. Xie D, Sham JST, Zeng WF et al (2003) Heterogenous expression and assiciation of β-catenin, p16, and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107:896-902
32. Su Y, Shrubsole MJ, Ness RM et al (2006) Immunohistochemical expression of Ki-67, Cyclin D1, β-catenin, cyclooxygenase-2 and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarray. Cancer Epidem Biomar 15:1719-1726
33. Bandapalli OR, Dihlmann S, Helwa R et al (2009) Transcriptional activation of the β-catenin gene at the invasion front of colorectal liver metastasis. J Pathol 218:370-379
34. Da Silva L, Parry S, Reid L et al (2008) Aberrant expression of Ecadherin in lobular carcinomas of the breast. Am J Surg Pathol 32:773-783
35. Muta H, Noguchi M, Kanai Y et al (1996) E-cadherin gene mutations in signet ring cell carcinoma of stomach. Jpn J Cancer Res 87:843-848
36. Kapiteijn E, Liefers GJ, Los LC et al (2001) Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 195:171-178